HCPLive 5 Stories in Under 5: Week of 03/23

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!

Interested in a more traditional, text rundown? Check out the HCPFive!

Top 5 Healthcare Headlines for March 23-30, 2025:

Zetomipzomib Shows Promise for Autoimmune Hepatitis in Phase 2a PORTOLA Trial

Zetomipzomib demonstrated steroid-sparing biochemical remissions in refractory autoimmune hepatitis patients, aligning with AASLD treatment guidelines in the Phase 2a PORTOLA trial.

Solriamfetol Significantly Reduces ADHD Symptoms in Axsome’s Phase 3 Trial

Solriamfetol met its primary endpoint in the Phase 3 FOCUS trial, significantly improving ADHD symptoms, with a higher proportion of patients achieving clinical response compared to placebo.

Sozinibercept for Wet AMD Misses Primary Endpoint in Phase 3 COAST Trial

Sozinibercept combined with aflibercept failed to meet the primary endpoint for visual acuity improvement in wet AMD, showing no added benefit over aflibercept monotherapy.

FDA Approves Gepotidacin (Blujepa) for Uncomplicated UTI

The FDA approved gepotidacin for uncomplicated urinary tract infections based on Phase 3 trials demonstrating non-inferiority to nitrofurantoin in female adults and adolescents.

FDA Issues CRL for Etripamil Nasal Spray (Cardamyst) in PSVT

The FDA issued a Complete Response Letter for etripamil nasal spray, citing manufacturing and control issues while confirming no concerns regarding its clinical safety or efficacy.